Oxadiazole Derivatives with Crth2 Receptor Activity
    2.
    发明申请
    Oxadiazole Derivatives with Crth2 Receptor Activity 审中-公开
    具有Crth2受体活性的恶二唑衍生物

    公开(公告)号:US20080312220A1

    公开(公告)日:2008-12-18

    申请号:US12094907

    申请日:2006-11-22

    CPC分类号: C07D271/06 C07D413/04

    摘要: Compounds of formula are CRTH2 ligands, useful for treatment of inflammatory, autoimmune, respiratory or allergy disease: wherein R1 is hydrogen or methyl and R2 is optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocyclyl having to 6 ring atoms; or R1 and R2, taken together with the carbon atom to which they are attached form an optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocyclyl having 4 to 6 ring atoms: or R1 and R2, taken together with the carbon atom to which they are attached form an optionally substituted cycloalkyl, or optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocyclyl ring having 4 to 6 ring atoms; R is hydrogen or an optional substitutent by 1, 2 or 3 optional substituents; A is hydrogen or C1-C3 alkyl; and ring Ar is an optionally substituted phenyl or 5- or 6-membered monocyclic heteroaryl ring.

    摘要翻译: 式的化合物是可用于治疗炎性,自身免疫,呼吸或过敏疾病的CRTH2配体:其中R1是氢或甲基,R2是任选取代的环烷基,或任选取代的具有6个环原子的非芳族杂环基; 或R 1和R 2与它们所连接的碳原子一起形成任选取代的环烷基,或任选取代的具有4-6个环原子的非芳族杂环基:或R 1和R 2与它们所在的碳原子一起 连接形成任选取代的环烷基,或任选取代的环烷基,或任选取代的具有4-6个环原子的非芳族杂环基; R是氢或任选的1,2或3个任选取代基的取代基; A是氢或C 1 -C 3烷基; 并且环Ar是任选取代的苯基或5-或6-元单环杂芳基环。

    Substituted Thiazoleacetic Acid as Crth2 Ligands
    3.
    发明申请
    Substituted Thiazoleacetic Acid as Crth2 Ligands 审中-公开
    取代噻唑乙酸作为Crth2配体

    公开(公告)号:US20080119456A1

    公开(公告)日:2008-05-22

    申请号:US11597839

    申请日:2005-05-30

    摘要: Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis; wherein X1 is —S—, —O—, —N═N—. —NR7—, —CR7═CR8—, —CR7═N—, wherein R7 and R8 are independently hydrogen or C1-C3 alkyl; A is a carboxyl group —COOH, or a carboxyl bioisostere; rings Ar2 and Ar3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; ring B is as defined for Ar2 and Ar3, or an optionally substituted N-pyrrolidinyl, N-piperidinyl or N-azepinyl ring; s is 0 or 1; L1, L2 and L4 are linker radicals as defined in the description; Q1 and Q2 represent substituents as defined in the description.

    摘要翻译: 式(I)化合物可用于治疗对CRTH2受体活性调节作用的疾病,例如哮喘,鼻炎,过敏性气道综合征和过敏性鼻炎支原体炎; 其中X 1是-S - , - O - , - N-N-。 -NR 7 - ,-CR 7 -CR 8 - ,-CR 7-N-,其中R R 7和R 8独立地是氢或C 1 -C 3烷基; A是羧基-COOH或羧基生物电子等排体; 环Ar 2和Ar 3各自独立地表示苯基或5或6元单环杂芳基环,或由5-或6-元环组成的双环系统 苯并稠合或稠合到5-或6-元单环杂芳基环的碳环或杂环,所述环或环系统任选被取代; 环B如Ar 2和Ar 3所定义,或任选取代的N-吡咯烷基,N-哌啶基或N-氮杂环丁基环; s为0或1; L1,L2和L4是描述中定义的连接基团; Q 1和Q 2表示如说明书中定义的取代基。

    CRTH2 receptor ligands for medicinal uses
    4.
    发明授权
    CRTH2 receptor ligands for medicinal uses 失效
    用于药用的CRTH2受体配体

    公开(公告)号:US08022063B2

    公开(公告)日:2011-09-20

    申请号:US11597873

    申请日:2005-05-30

    IPC分类号: A01N43/00 C07D231/00

    摘要: Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A1, is hydrogen or methyl; ring Ar1 is an optionally substituted phenyl ring 5- or 6-membered monocyclic heteroaryl ring, in which AA1CHO— and L2 are linked to adjacent ring atoms; rings Are2, Ar3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.

    摘要翻译: 式(I)化合物可用于治疗对CRTH2受体活性调节作用的疾病,例如哮喘,鼻炎,过敏性气道综合征和过敏性鼻炎支原体,其中A表示羧基-COON或羧基生物电子等排体; A1,是氢或甲基; 环Ar1是任选取代的苯环5-或6-元单环杂芳基环,其中AA1CHO-和L2与相邻的环原子连接; 环A 2,Ar 3各自独立地表示苯基或5-或6-元单环杂芳基环,或由5-或6-元碳环或杂环组成的双环系统,其被苯并稠合或稠合至5-或 6元单环杂芳基环,所述环或环系统任选被取代; t为0或1; L2和L3是如说明书中定义的连接基团。

    CRTH2 Receptor Ligands For Medicinal Uses
    5.
    发明申请
    CRTH2 Receptor Ligands For Medicinal Uses 失效
    CRTH2受体配体用于药用

    公开(公告)号:US20090099189A1

    公开(公告)日:2009-04-16

    申请号:US11597873

    申请日:2005-05-30

    摘要: Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A1, is hydrogen or methyl; ring Ar1 is an optionally substituted phenyl ring 5- or 6-membered monocyclic heteroaryl ring, in which AA1CHO— and L2 are linked to adjacent ring atoms; rings Are2, Ar3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.

    摘要翻译: 式(I)化合物可用于治疗对CRTH2受体活性调节作用的疾病,例如哮喘,鼻炎,过敏性气道综合征和过敏性鼻炎支原体,其中A表示羧基-COON或羧基生物电子等排体; A1,是氢或甲基; 环Ar1是任选取代的苯环5-或6-元单环杂芳基环,其中AA1CHO-和L2与相邻的环原子连接; 环A 2,Ar 3各自独立地表示苯基或5-或6-元单环杂芳基环,或由5-或6-元碳环或杂环组成的双环系统,其被苯并稠合或稠合至5-或 6元单环杂芳基环,所述环或环系统任选被取代; t为0或1; L2和L3是如说明书中定义的连接基团。